Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.41 |
| ▸ | AOC1 | P19801 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28229161 | 0.86 | IMPDH2 (0.41) | IMPDH2AOC1AOC3POLBTSHR | |
| SCHEMBL3823546 | 0.83 | POLB (0.43) | POLBTSHRHPGDMAPK1HSD17B10 | |
| SCHEMBL20189707 | 0.83 | KDM4E (0.42) | IMPDH2AOC1AOC3MAPTCA12 | |
| SCHEMBL3588383 | 0.81 | IMPDH2 (0.38) | IMPDH2AOC1AOC3MAPTCA12 | |
| SCHEMBL8811300 | 0.79 | POLB (0.38) | POLBTSHRHPGDMAPK1HSD17B10 | |
| SCHEMBL4160377 | 0.76 | CA12 (0.57) | AOC1AOC3POLBHPGDMAPK1 | |
| SCHEMBL4956799 | 0.75 | ADRA2A (0.40) | POLBTSHRHPGDMAPK1HSD17B10 | |
| SCHEMBL4958013 | 0.73 | POLB (0.40) | POLBHPGDHSD17B10MAPTTGFBR1 | |
| SCHEMBL4608367 | 0.73 | ALDH1A1 (0.55) | TSHRHPGDMAPK1HSD17B10CA12 | |
| SCHEMBL15778646 | 0.73 | AOC3 (0.46) | AOC1AOC3MAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | IMPDH2 1439/4885AOC1 1042/4885AOC3 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.